KANK1 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function studies of the KANK1 gene. This heterogeneous pool of HAP1 cells carries diverse CRISPR/Cas9-mediated disruptions of the target gene, providing a robust model for population-level phenotypic analyses without the biases associated with monoclonal selection. The polyclonal format enables efficient parallel functional screening and bulk signaling studies, supporting assays that require consistent genetic perturbation across a cellular ensemble, such as dose-response experiments and omics analyses.
The HAP1 cell line is a human near-haploid chronic myeloid leukemia (CML) derivative of the KBM-7 cell line, exhibiting adherent, fibroblast-like morphology. Its near-haploid karyotype renders it a powerful platform for functional genomics and genetic screening, as single-copy gene disruptions readily reveal loss-of-function phenotypes. Widely employed in cancer research, HAP1 cells facilitate mechanistic studies of signaling pathways, cell adhesion, migration, and therapeutic response, making them an ideal host for KANK1 knockout studies.
KANK1 encodes a scaffold protein that orchestrates actin cytoskeleton dynamics and focal adhesion turnover by integrating Rho family GTPase signaling and Wnt/??-catenin regulation. At focal adhesions, KANK1 directly binds talin, paxillin, and vinculin, and interacts with p115RhoGEF and KRIT1 (CCM1) to inhibit RhoA-ROCK signaling, thereby suppressing actin stress fiber formation. Simultaneously, KANK1 promotes Rac1 activation through the Rac1-PAK pathway. In the cytoplasm, KANK1 sequesters ??-catenin, preventing its nuclear translocation and TCF/LEF-mediated transcriptional activation. This dual regulatory mechanism positions KANK1 as a critical node where integrin-FAK-Src and Wnt-??-catenin-TCF pathways converge, with upstream regulation by the miR-200 family and TGF-?? signaling.
In HAP1 cells, KANK1 loss disrupts the balance between RhoA and Rac1 activities, leading to altered actin architecture, enhanced stress fiber formation, and impaired focal adhesion dynamics. The near-haploid background amplifies these phenotypic readouts, facilitating clear dissection of KANK1’s tumor-suppressive functions. Given KANK1’s association with cerebral cavernous malformations through its interaction with CCM proteins, and its putative role as a tumor suppressor in renal cell carcinoma, colorectal cancer, and ovarian cancer, this knockout model is valuable for investigating disease mechanisms and drug sensitivity. For example, KANK1-deficient HAP1 cells may exhibit altered response to chemotherapeutic agents like cisplatin, and can be used to study ??-catenin-dependent transcription via TOP/FOP reporter assays.
This polyclonal knockout cell product supports a broad spectrum of applications, including cell migration and invasion assays, focal adhesion visualization, RhoA/Rac1 activity pull-downs, and Wnt/??-catenin pathway analysis. Researchers can utilize these cells to explore KANK1-dependent tumor suppression, cerebral cavernous malformation pathophysiology, and integrin-mediated signaling. Additionally, HAP1 KANK1 knockout cells are suitable for genetic and pharmacological modifier screens and cancer drug sensitivity profiling. For further information or to discuss specific experimental requirements, please contact Ascent Research.
